S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
Log in

NASDAQ:THOR - Synthorx Stock Price, Forecast & News

$67.99
0.00 (0.00 %)
(As of 02/18/2020 04:00 PM ET)
Today's Range
$67.99
Now: $67.99
$67.99
50-Day Range
$67.99
MA: $68.48
$70.86
52-Week Range
$11.05
Now: $67.99
$71.90
VolumeN/A
Average Volume474,507 shs
Market Capitalization$2.20 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:THOR
CUSIP88517530
Phone858-750-4700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.72 per share

Profitability

Net Income$-56,610,000.00

Miscellaneous

Employees39
Market Cap$2.20 billion
Next Earnings Date3/10/2020 (Estimated)
OptionableNot Optionable

Receive THOR News and Ratings via Email

Sign-up to receive the latest news and ratings for THOR and its competitors with MarketBeat's FREE daily newsletter.


Synthorx (NASDAQ:THOR) Frequently Asked Questions

What is Synthorx's stock symbol?

Synthorx trades on the NASDAQ under the ticker symbol "THOR."

How were Synthorx's earnings last quarter?

Synthorx Inc (NASDAQ:THOR) posted its earnings results on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.12. View Synthorx's Earnings History.

When is Synthorx's next earnings date?

Synthorx is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Synthorx.

What price target have analysts set for THOR?

5 analysts have issued 12-month price targets for Synthorx's shares. Their forecasts range from $30.00 to $68.00. On average, they anticipate Synthorx's share price to reach $53.80 in the next year. This suggests that the stock has a possible downside of 20.9%. View Analyst Price Targets for Synthorx.

What is the consensus analysts' recommendation for Synthorx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synthorx.

What are Wall Street analysts saying about Synthorx stock?

Here are some recent quotes from research analysts about Synthorx stock:
  • 1. According to Zacks Investment Research, "Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company's product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. " (1/10/2020)
  • 2. HC Wainwright analysts commented, "Our 12-month, $30 price target on shares of Synthorx is based on a 12-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.5, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2029. We assign a 9% POS for THOR-707, which we anticipate could be developed in NSCLC, RCC, melanoma, and urothelial cancer. These indications together represent about 95% of our target with NSCLC being the biggest driver of valuation, elaborated upon subsequently." (5/1/2019)

Has Synthorx been receiving favorable news coverage?

Media stories about THOR stock have been trending extremely negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synthorx earned a news impact score of -4.0 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Synthorx.

Who are some of Synthorx's key competitors?

What other stocks do shareholders of Synthorx own?

Who are Synthorx's key executives?

Synthorx's management team includes the folowing people:
  • Dr. Laura K. Shawver, CEO, Pres & Director (Age 61)
  • Dr. Floyd E. Romesberg, Scientific Founder & Director (Age 53)
  • Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 56)
  • Dr. Joseph Leveque, Chief Medical Officer (Age 58)
  • Terry L. Button, VP & Director

When did Synthorx IPO?

(THOR) raised $100 million in an initial public offering on Friday, December 7th 2018. The company issued 9,100,000 shares at a price of $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Synthorx's major shareholders?

Synthorx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ARP Americas LP (1.48%), Goldman Sachs Group Inc. (0.78%), State Street Corp (0.49%), Chicago Capital Management LLC (0.46%), Credit Suisse AG (0.40%) and Magnetar Financial LLC (0.38%). Company insiders that own Synthorx stock include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Institutional Ownership Trends for Synthorx.

Which major investors are selling Synthorx stock?

THOR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Russell Investments Group Ltd. and First Trust Advisors LP. View Insider Buying and Selling for Synthorx.

Which major investors are buying Synthorx stock?

THOR stock was acquired by a variety of institutional investors in the last quarter, including ARP Americas LP, Chicago Capital Management LLC, Credit Suisse AG, Magnetar Financial LLC, Oxford Asset Management LLP, Glazer Capital LLC, Fort Baker Capital Management LP and Bank of America Corp DE. Company insiders that have bought Synthorx stock in the last two years include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Insider Buying and Selling for Synthorx.

How do I buy shares of Synthorx?

Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Synthorx's stock price today?

One share of THOR stock can currently be purchased for approximately $67.99.

How big of a company is Synthorx?

Synthorx has a market capitalization of $2.20 billion. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis. Synthorx employs 39 workers across the globe.View Additional Information About Synthorx.

What is Synthorx's official website?

The official website for Synthorx is http://www.synthorx.com/.

How can I contact Synthorx?

Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected]


MarketBeat Community Rating for Synthorx (NASDAQ THOR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  408 (Vote Outperform)
Underperform Votes:  443 (Vote Underperform)
Total Votes:  851
MarketBeat's community ratings are surveys of what our community members think about Synthorx and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Swap

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel